1. Clinical results of EGFR-targeted therapies in advanced colorectal cancer
- Author
-
Giuseppe Colucci, Vittorio Gebbia, Franco Morelli, Antonio Maria Grimaldi, Luigi Manzione, Carlo Arcara, Evaristo Maiello, and Francesco Giuliani
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Cetuximab ,business.industry ,Colorectal cancer ,medicine.medical_treatment ,Cancer ,medicine.disease ,Surgery ,Targeted therapy ,FOLFOX ,Internal medicine ,FOLFIRI ,Medicine ,Panitumumab ,business ,medicine.drug - Abstract
This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents – cetuximab and panitumumab – employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens – FOLFIRI and FOLFOX – has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects.
- Published
- 2008